Fertilisation

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on: 
Wednesday, March 20, 2024
Infertility, TMSC, Pregnancy rate, IVF, IUI, Pregnancy, Fertilisation, Woman, Male, Safety, Literature, FDA, ICSI, Insemination, Physician, Birth control

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
  • “These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
  • “The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
  • The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

China In-Vitro Fertilization Market Research Report 2023-2030 Featuring Vitrolife, Cloudnine, Nova IVI Fertility, Monash, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
General Health, Other Health, Consumer, Health, Baby, Maternity, Consciousness, Infertility, Prevalence, IVF, Sterilization, Fertility, Fertilisation, Woman, Male, Infection, Patient safety, ICSI, Birth control

Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.

Key Points: 
  • Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.
  • Disposable devices are predicted to be among the instruments used considerably in the China In-Vitro Fertilization (IVF) market.
  • ICSI IVF is foreseen to be among the considerably utilized processes in the China In-Vitro Fertilization (IVF) market.
  • Fertility clinics are projected to experience a considerable increase in utilization in the China In-Vitro Fertilization (IVF) market.

Talkspace Launches Health Collective to Further Expand Accessibility to Healthcare Services

Retrieved on: 
Tuesday, March 19, 2024
Technology, Mental Health, Public Policy, Government, Health Technology, Healthcare Reform, Telemedicine, Virtual Medicine, Audio, Video, Health, General Health, Education, Mental, Patient, Mental health, Talkspace, Fertilisation, Nursing

Today, Talkspace , a leading online behavioral health company, announced the launch of Health Collective , a new wellness ecosystem featuring Oura , Evernow , Bicycle Health , Conceive , Options MD , and more.

Key Points: 
  • Today, Talkspace , a leading online behavioral health company, announced the launch of Health Collective , a new wellness ecosystem featuring Oura , Evernow , Bicycle Health , Conceive , Options MD , and more.
  • The launch of Health Collective is part of Talkspace’s focus on bolstering strategic partnerships, driven by an understanding of the evolving healthcare landscape and the diverse needs of clients and patients.
  • With an array of specialty partners involved in Health Collective, Talkspace will bring comprehensive, whole-person care to market more quickly and efficiently than ever before.
  • “At Talkspace, we recognize the need for more accessible behavioral health and specialty health resources,” said Natalie Cummins, Chief Business Officer at Talkspace.

ResumeBuilder.com Survey Reveals 3 in 10 Workers Are Unlikely To Consider Jobs in States With IVF Restrictions

Retrieved on: 
Thursday, April 4, 2024
Fertilisation, Private practice, Employment, IVF, Ageing, Work, Legislation, Woman

SEATTLE, April 4, 2024 /PRNewswire-PRWeb/ -- ResumeBuilder.com, the premier resource for professional resume templates and career advice, has published a recent survey report investigating the impact of reproductive care public policies on workers' employment location preferences. The report also provides valuable insights into workers' attitudes toward legislation prohibiting in vitro fertilization. The survey collected responses from 1,250 employed adults in the United States.

Key Points: 
  • The survey collected responses from 1,250 employed adults in the United States.
  • "Public policies affecting women's health care are impacting where Americans want to live and work," says Stacie Haller.
  • Within this group, 51 percent say there is nothing that would make them more likely to consider a job offer in one of these states.
  • Among respondents, 30 percent report they are unlikely to consider a job offer in a state that has passed legislation effectively banning IVF.

Gameto Announces Patient Experience Data Demonstrating Investigational In Vitro Maturation Solution Well Tolerated with Higher Patient Satisfaction Rates than Conventional Fertility Stimulation

Retrieved on: 
Tuesday, April 2, 2024
Disease, Biotechnology, Data analysis, Abdominal pain, Patient, IVF, COS, Female, Fertility, Manuscript, Fertilisation, Freezing, Woman, OHSS, Pain, Vomiting, IPSC, FDA, IVM, Ovarian hyperstimulation syndrome, Cell, Birth control

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).

Key Points: 
  • The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).
  • "We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol.
  • Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.
  • [1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS.

Precision Farming Software Market worth $3.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, March 19, 2024
Cloud, Statistics, Temperature, Pesticide, Farmer, Component, Forecasting, VRT, Variable Rate Application, Trimble Inc., Hydroponics, GPS, Drought, John Deere, Fertilisation, Weather, Drone, Investment, Sensor, AGCO, Fertilizer, Water, Forestry, Livestock, Production, Polyethylene, Privacy, Kubota, CNH Industrial, Hardware, Agriculture

The increasing integration of weather tracking and forecasting into precision farming software is driven by various facets of farming, influencing critical activities such as planting, irrigation, fertilization, and pest management.

Key Points: 
  • The increasing integration of weather tracking and forecasting into precision farming software is driven by various facets of farming, influencing critical activities such as planting, irrigation, fertilization, and pest management.
  • The scalability, accessibility, and data integration capabilities of cloud-based precision farming software provide farmers with essential tools to optimize their operations, enhance productivity, and promote sustainability.
  • Variable rate technology (VRT) is increasingly becoming a cornerstone of precision farming software, driven by several pivotal factors.
  • The America stands out as the swiftest expanding sector in the precision farming software industry .

Precision Farming Software Market worth $3.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, March 19, 2024
Cloud, Statistics, Temperature, Pesticide, Farmer, Component, Forecasting, VRT, Variable Rate Application, Trimble Inc., Hydroponics, GPS, Drought, John Deere, Fertilisation, Weather, Drone, Investment, Sensor, AGCO, Fertilizer, Water, Forestry, Livestock, Production, Polyethylene, Privacy, Kubota, CNH Industrial, Hardware, Agriculture

The increasing integration of weather tracking and forecasting into precision farming software is driven by various facets of farming, influencing critical activities such as planting, irrigation, fertilization, and pest management.

Key Points: 
  • The increasing integration of weather tracking and forecasting into precision farming software is driven by various facets of farming, influencing critical activities such as planting, irrigation, fertilization, and pest management.
  • The scalability, accessibility, and data integration capabilities of cloud-based precision farming software provide farmers with essential tools to optimize their operations, enhance productivity, and promote sustainability.
  • Variable rate technology (VRT) is increasingly becoming a cornerstone of precision farming software, driven by several pivotal factors.
  • The America stands out as the swiftest expanding sector in the precision farming software industry .

Rachio Releases New Gardening Products for Start of Spring

Retrieved on: 
Tuesday, March 19, 2024
Umbrella, Health, Growth, Gardening, Transplanter, Weed control, Fertilisation, Soil

DENVER, March 19, 2024 /PRNewswire/ -- Rachio, the leading smart-yard brand known for its sustainable watering solutions, kicks off spring with an exciting lineup of new products now available on Rachio Market, the brand's dedicated marketplace. Now entering its third year, Rachio Market is the go-to destination for homeowners seeking intelligent, eco-friendly solutions for their outdoor spaces. In addition to Rachio's award-winning smart-watering devices, notably the #1-rated Rachio 3 Smart Sprinkler Controller and Smart Hose Timer, the brand offers premier landscaping tools, outdoor tech products, and more, all intentionally selected to help users optimize their yards, expand their smart home ecosystems, and Connect Outside.

Key Points: 
  • Explore Rachio-Branded and Partner Products Plus 20% Off Rachio Products, Now Available on Rachio.com
    DENVER, March 19, 2024 /PRNewswire/ -- Rachio , the leading smart-yard brand known for its sustainable watering solutions, kicks off spring with an exciting lineup of new products now available on Rachio Market , the brand's dedicated marketplace.
  • "We curate products that enhance outdoor enjoyment for our community and offer them quality products they can trust."
  • Featured in Rachio's Start of Spring Product Guide , these products include:
    MySoil Test Kit : Understanding soil health is crucial for a thriving lawn.
  • Through March 24th, Rachio is offering 20% off Rachio devices, including the Smart Hose Timer and Rachio 3, 15% off the Sunday Spring Starter Kit, and 30% off the Above Umbrella .

Paralyzed Veterans of America issues statement in response to VA's expansion of IVF

Retrieved on: 
Monday, March 11, 2024
PVA, Disability, Fertilisation, IVF, Family, Congress, Marital status, Infertility, Birth control

WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.

Key Points: 
  • WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.
  • "PVA has long supported increased access to assisted reproductive technologies, including in vitro fertilization, through VA for catastrophically disabled veterans to grow their families.
  • Blake continued, "While VA's announcement is a tremendous step forward, more advancements are still needed.
  • PVA has long called on Congress to authorize VA to provide assisted reproductive technology, including IVF, surrogacy, and gamete donation at VA for any veterans enrolled in VA health care.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Wednesday, March 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.